 In some patients, the duration of dual antiplatelet treatment could be individualized taking into consideration the particular risks of that patients. In patients with very high bleeding risk e.g. patients with a history of repeated bleedings, the duration of dual antiplatelet treatment could be shortened to 6 weeks. After that, if a control TEE yields satisfactory results, clopidogrel could be discontinued and patients could be left on aspirin monotherapy only. Six-weeks of dual antiplatelet treatment has been recently shown to be sufficient after LAA occlusion. 16 On the other hand, in patients with a significant thrombotic risk e.g. with a history of repeated cardioembolic events, but without a history of overt bleeding, the duration of dual antiplatelet treatment could be prolonged to 6 months. The decision i.e., the assessment of the individual risk profile of an implanted patient and the patient-specific approach will be left to the discretion of the treating physician. 